1. hypersensitivity to components of the study drug. 2. impossibility of ct procedure (for example, gypsumdressing or metal structures in the field of imaging). 3. obstacles or inability to perform intramuscular injections and / or inhalations 4. arterial hypotension (a decrease in blood pressure (bp) below 100/60 mm hg) at the time of screening and / or a history of hypotensive crises. 5. the need for the use of drugs from the list of prohibited therapies. 6. availability of criteria for severe and extremely severe disease at the time of screening 7. presence within 6 months prior to screening of a probable or confirmed case of moderate covid-19 8. history of presumptive or confirmed covid-19 caseof moderate, severe and extremely severe course ofthe disease. 9. vaccination less than 4 weeks prior to screening. 10. the need for treatment in the intensive care unit at the time of screening. 11. impaired liver function (ast and/or alt ≥ 2 unland/or total bilirubin ≥ 1.5 unl) at the time ofscreening. 12. renal impairment (gfr \< 60 ml/min) at the time of screening. 13. positive testing for hiv, syphilis, hepatitis b and/or c. 14. chronic heart failure fc iii-iv according to new york heart association (nyha) functional classification. 15. malignancies in the past medical history. 16. alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening. 17. epilepsy in history. 18. schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening. 19. severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study). 20. any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study. 21. patient's unwillingness or inability to comply with procedures of the study protocol (in the opinion of physician investigator). 22. pregnant or nursing women or women planning pregnancy. 23. participation in another clinical study for 3 monthsprior to inclusion in the study. 24. other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.

1. hypersensitivity to components of the study drug. 2. impossibility of ct procedure (for example, gypsumdressing or metal structures in the field of imaging). 3. obstacles or inability to perform intramuscular injections and / or inhalations 4. arterial hypotension (a decrease in blood pressure (bp) below 100/60 mm hg) at the time of screening and / or a history of hypotensive crises. 5. the need for the use of drugs from the list of prohibited therapies. 6. availability of criteria for severe and extremely severe disease at the time of screening 7. presence within 6 months prior to screening of a probable or confirmed case of moderate covid-19 8. history of presumptive or confirmed covid-19 caseof moderate, severe and extremely severe course ofthe disease. 9. vaccination less than 4 weeks prior to screening. 10. the need for treatment in the intensive care unit at the time of screening. 11. impaired liver function (ast and/or alt ≥ 2 unland/or total bilirubin ≥ 1.5 unl) at the time ofscreening. 12. renal impairment (gfr \< 60 ml/min) at the time of screening. 13. positive testing for hiv, syphilis, hepatitis b and/or c. 14. chronic heart failure fc iii-iv according to new york heart association (nyha) functional classification. 15. malignancies in the past medical history. 16. alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening. 17. epilepsy in history. 18. schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening. 19. severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study). 20. any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study. 21. patient's unwillingness or inability to comply with procedures of the study protocol (in the opinion of physician investigator). 22. pregnant or nursing women or women planning pregnancy. 23. participation in another clinical study for 3 monthsprior to inclusion in the study. 24. other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.

hypersensitivity to components of the study drug. impossibility of ct procedure (for example, gypsumdressing or metal structures in the field of imaging). obstacles or inability to perform intramuscular injections and / or inhalations arterial hypotension (a decrease in blood pressure (bp) below 100/60 mm hg) at the time of screening and / or a history of hypotensive crises. the need for the use of drugs from the list of prohibited therapies. availability of criteria for severe and extremely severe disease at the time of screening presence within 6 months prior to screening of a probable or confirmed case of moderate covid-19 history of presumptive or confirmed covid-19 caseof moderate, severe and extremely severe course ofthe disease. vaccination less than 4 weeks prior to screening. the need for treatment in the intensive care unit at the time of screening. impaired liver function (ast and/or alt ≥ 2 unland/or total bilirubin ≥ 1.5 unl) at the time ofscreening. renal impairment (gfr < 60 ml/min) at the time of screening. positive testing for hiv, syphilis, hepatitis b and/or c. chronic heart failure fc iii-iv according to new york heart association (nyha) functional classification. malignancies in the past medical history. alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening. epilepsy in history. schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening. severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study). any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study. patient's unwillingness or inability to comply with procedures of the study protocol (in the opinion of physician investigator). pregnant or nursing women or women planning pregnancy. participation in another clinical study for 3 monthsprior to inclusion in the study. other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.

hypersensitivity to components of the study drug. impossibility of ct procedure (for example, gypsumdressing or metal structures in the field of imaging). obstacles or inability to perform intramuscular injections and / or inhalations arterial hypotension (a decrease in blood pressure (bp) below 100/60 mm hg) at the time of screening and / or a history of hypotensive crises. the need for the use of drugs from the list of prohibited therapies. availability of criteria for severe and extremely severe disease at the time of screening presence within 6 months prior to screening of a probable or confirmed case of moderate covid-19 history of presumptive or confirmed covid-19 caseof moderate, severe and extremely severe course ofthe disease. vaccination less than 4 weeks prior to screening. the need for treatment in the intensive care unit at the time of screening. impaired liver function (ast and/or alt ≥ 2 unland/or total bilirubin ≥ 1.5 unl) at the time ofscreening. renal impairment (gfr < 60 ml/min) at the time of screening. positive testing for hiv, syphilis, hepatitis b and/or c. chronic heart failure fc iii-iv according to new york heart association (nyha) functional classification. malignancies in the past medical history. alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening. epilepsy in history. schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening. severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study). any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study. patient's unwillingness or inability to comply with procedures of the study protocol (in the opinion of physician investigator). pregnant or nursing women or women planning pregnancy. participation in another clinical study for 3 monthsprior to inclusion in the study. other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.